• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹主动脉瘤中的止血因素和管腔内血栓厚度。继发性纤溶是否相关?

Haemostatic factors and intraluminal thrombus thickness in abdominal aortic aneurysm. Is secondary fibrinolysis relevant?

机构信息

Department of Laboratory Diagnostics and Molecular Medicine, Pomeranian Medical University, Szczecin, Poland.

出版信息

J Physiol Pharmacol. 2013 Jun;64(3):321-30.

PMID:23959729
Abstract

Many circulating haemostatic markers have been investigated in relation to the abdominal aortic aneurysm (AAA) size, growth as well as intraluminal thrombus (ILT) size. However, the results of these studies seem to be uncertain and inconsistent. The first aim of the present study was to compare the haemostatic parameters of fibrinolysis and some of thrombotic markers in patients with AAA and controls. We also examined the relationship between those parameters and both maximum aneurysm diameter and intraluminal thrombus thickness. Tissue plasminogen activator (t-PA), plasminogen activator inhibitor (PAI-1), fibrinogen (Fb), D-dimer, prothrombin fragments 1 and 2 (F1+2), thromboxane B2 (TXB2) and lipids profile were measured in 36 patients with AAA and 30 controls. The mean maximum aortic diameter in patients with the AAA was 59±12 mm (range 42-100). The mean ILT thickness was 32±10 mm (range 8-56). Among haemostatic factors, t-PA and D-dimer levels, but not PAI-1, were significantly higher in subjects with the AAA. There was a strong positive correlation between thickness of intraluminal thrombus and maximum aneurysm size (r=0.69, p<0.0001), and the negative relationship between t-PA and ILT thickness (r= -0.53, p=0.001) as well as aneurysm diameter (r= -0.38, p=0.023). Higher plasma concentrations of t-PA and D-dimer support the hypothesis that the secondary fibrinolysis plays an important role in the pathogenesis of the aortic abdominal aneurysm formation. In addition, the negative correlation between t-PA plasma level and ILT thickness suggests that thrombotic/fibrinolysis imbalance may favour accelerated formation of intraluminal thrombus and possibly aneurysm progression.

摘要

许多与腹主动脉瘤(AAA)大小、生长以及管腔内血栓(ILT)大小相关的循环止血标志物已被研究。然而,这些研究的结果似乎不确定且不一致。本研究的首要目的是比较 AAA 患者和对照组的纤溶和一些血栓形成标志物的止血参数。我们还检查了这些参数与最大动脉瘤直径和管腔内血栓厚度之间的关系。组织型纤溶酶原激活物(t-PA)、纤溶酶原激活物抑制剂(PAI-1)、纤维蛋白原(Fb)、D-二聚体、凝血酶原片段 1 和 2(F1+2)、血栓烷 B2(TXB2)和血脂谱在 36 名 AAA 患者和 30 名对照组中进行了测量。AAA 患者的平均最大主动脉直径为 59±12mm(范围 42-100)。平均 ILT 厚度为 32±10mm(范围 8-56)。在止血因子中,t-PA 和 D-二聚体水平,但不是 PAI-1,在 AAA 患者中明显升高。管腔内血栓厚度与最大动脉瘤大小之间存在强烈的正相关(r=0.69,p<0.0001),t-PA 与 ILT 厚度之间呈负相关(r=-0.53,p=0.001)以及动脉瘤直径(r=-0.38,p=0.023)。较高的 t-PA 和 D-二聚体血浆浓度支持继发性纤溶在腹主动脉瘤形成的发病机制中起重要作用的假说。此外,t-PA 血浆水平与 ILT 厚度之间的负相关表明血栓形成/纤溶失衡可能有利于管腔内血栓形成的加速和可能的动脉瘤进展。

相似文献

1
Haemostatic factors and intraluminal thrombus thickness in abdominal aortic aneurysm. Is secondary fibrinolysis relevant?腹主动脉瘤中的止血因素和管腔内血栓厚度。继发性纤溶是否相关?
J Physiol Pharmacol. 2013 Jun;64(3):321-30.
2
Plasma D-dimer as a predictor of intraluminal thrombus burden and progression of abdominal aortic aneurysm.血浆 D-二聚体作为腹主动脉瘤管腔内血栓负荷和进展的预测因子。
Life Sci. 2020 Jan 1;240:117069. doi: 10.1016/j.lfs.2019.117069. Epub 2019 Nov 18.
3
Tissue factor levels and the fibrinolytic system in thin and thick intraluminal thrombus and underlying walls of abdominal aortic aneurysms.腹主动脉瘤腔内薄血栓和厚血栓及其下方血管壁中的组织因子水平与纤溶系统
J Vasc Surg. 2018 Dec;68(6S):30S-37S. doi: 10.1016/j.jvs.2017.12.030. Epub 2018 Mar 20.
4
Intraluminal abdominal aortic aneurysm thrombus is associated with disruption of wall integrity.腹主动脉瘤管腔内血栓与管壁完整性破坏有关。
J Vasc Surg. 2013 Jan;57(1):77-83. doi: 10.1016/j.jvs.2012.07.003. Epub 2012 Nov 3.
5
Effect of endovascular and open abdominal aortic aneurysm repair on thrombin generation and fibrinolysis.血管内和开放腹主动脉瘤修复对凝血酶生成和纤维蛋白溶解的影响。
J Vasc Surg. 2013 Jan;57(1):103-7. doi: 10.1016/j.jvs.2012.07.024. Epub 2012 Nov 7.
6
Fibrinolysis in patients with an abdominal aortic aneurysm with special emphasis on rupture and shock.腹主动脉瘤患者的纤维蛋白溶解,特别强调破裂和休克。
J Thromb Haemost. 2008 Jan;6(1):147-50. doi: 10.1111/j.1538-7836.2007.02791.x. Epub 2007 Oct 8.
7
Raised plasma fibrinogen concentration in patients with abdominal aortic aneurysm.腹主动脉瘤患者血浆纤维蛋白原浓度升高。
Angiology. 2006 Oct-Nov;57(5):607-14. doi: 10.1177/0003319706293132.
8
Haemostatic markers in patients with abdominal aortic aneurysm and the impact of aneurysm size.腹主动脉瘤患者的止血标志物及动脉瘤大小的影响
Thromb Res. 2009 Sep;124(4):423-6. doi: 10.1016/j.thromres.2009.01.016. Epub 2009 Mar 6.
9
Homocysteine-Enhanced Proteolytic and Fibrinolytic Processes in Thin Intraluminal Thrombus and Adjacent Wall of Abdominal Aortic Aneurysm: Study In Vitro.同型半胱氨酸增强的薄腔内血栓和腹主动脉瘤壁的蛋白水解和纤维蛋白溶解过程:体外研究。
Biomed Res Int. 2018 Dec 12;2018:3205324. doi: 10.1155/2018/3205324. eCollection 2018.
10
Topology of the fibrinolytic system within the mural thrombus of human abdominal aortic aneurysms.人腹主动脉瘤壁内血栓中纤维蛋白溶解系统的拓扑结构。
J Pathol. 2007 May;212(1):20-8. doi: 10.1002/path.2148.

引用本文的文献

1
Antiplatelet or Anticoagulant Therapy for Abdominal Aortic Aneurysms: Growth and Clinical Outcomes.腹主动脉瘤的抗血小板或抗凝治疗:生长情况及临床结局
Anatol J Cardiol. 2024 Jan 29;28(4):187-93. doi: 10.14744/AnatolJCardiol.2023.3719.
2
Intraluminal thrombus: Innocent bystander or factor in abdominal aortic aneurysm pathogenesis?腔内血栓:腹主动脉瘤发病机制中的无辜旁观者还是因素?
JVS Vasc Sci. 2021 May 18;2:159-169. doi: 10.1016/j.jvssci.2021.02.001. eCollection 2021.
3
A super-elderly case of abdominal aortic aneurysm associated with chronic disseminated intravascular coagulation.
一例与慢性弥散性血管内凝血相关的腹主动脉瘤超老年病例。
J Cardiol Cases. 2014 Nov 26;11(2):48-51. doi: 10.1016/j.jccase.2014.10.005. eCollection 2015 Feb.
4
The Abdominal Aortic Aneurysm and Intraluminal Thrombus: Current Concepts of Development and Treatment.腹主动脉瘤与腔内血栓:当前的发病机制与治疗理念。
Front Cardiovasc Med. 2015 May 26;2:19. doi: 10.3389/fcvm.2015.00019. eCollection 2015.